Manufacturer
Amgen Biopharmaceuticals Malaysia Sdn Bhd
Contents
Panitumumab
Indication
Adults w/ wild-type RAS metastatic colorectal cancer (mCRC): 1st-line in combination w/ FOLFOX; 2nd-line in combination w/ FOLFIRI for patients who have received 1st-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Monotherapy after failure of fluoropyrimidine-, oxaliplatin- & irinotecan-containing chemotherapy regimens.
Drug interaction
High incidence of severe diarrhoea w/ IFL. Increased toxicity w/ bevacizumab & chemotherapy.
Amgen Biopharmaceuticals Malaysia Sdn Bhd
Contents
Panitumumab
Indication
Adults w/ wild-type RAS metastatic colorectal cancer (mCRC): 1st-line in combination w/ FOLFOX; 2nd-line in combination w/ FOLFIRI for patients who have received 1st-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Monotherapy after failure of fluoropyrimidine-, oxaliplatin- & irinotecan-containing chemotherapy regimens.
Drug interaction
High incidence of severe diarrhoea w/ IFL. Increased toxicity w/ bevacizumab & chemotherapy.
Inquiry - Vectibix 100mg Concentrate for Solution for Infusion